A Phase 3, Multicenter, 12-Week, Double-Blind and 40-Week Open Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Knee
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Ibuprofen (Primary)
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Techfields Pharma
- 04 Dec 2017 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.
- 04 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 30 May 2018.
- 10 Oct 2017 Planned initiation date changed from 30 Jun 2017 to 30 Nov 2017.